Joint final report of Phase III trials demonstrate positive outcomes from combination of PCV chemotherapy and RT in patients with anaplastic oligodendroglial tumors

The addition of procarbazine, lomustine, and vincristine (PCV) chemotherapy to Radiation Therapy (RT) was shown to lengthen both disease control and survival relative to RT alone as first-line therapy following surgery on the NRG/Radiation Therapy Oncology Group (RTOG) 9402 and European Organization for the Research and Treatment of Cancer (EORTC) 26951 clinical trials. The results reinforce the importance of PCV as a therapeutic chemotherapy regimen for gliomas, despite a transition, since these studies were launched, to temozolomide due to its lower toxicity and perceived equivalence of efficacy. Updated mature long-term results from the RTOG and EORTC studies were recently published as a joint report in the Journal of Clinical Oncology.

Patients were eligible if they had anaplastic oligodendroglioma or anaplastic oligo-astrocytoma, had not undergone radiotherapy or chemotherapy, and had adequate marrow, liver, and renal function. In the EORTC study, 368 eligible patients were randomized to RT with or without 6 cycles of PCV after RT.  In the RTOG study, 289 eligible patients were randomized to RT or 4 cycles of intensified PCV before RT.

In these updated analyses, after nearly 20 years of median follow-up in both studies, overall survival (OS) rates among patients with chromosome 1p19q codeleted tumors randomized to PCV-chemoradiotherapy at 10, 15, and 20 years were 57%, 51%, and 37% in the EORTC study and 57%, 46%, and 37% in the RTOG study vs. 43%, 26%, and 14% and 32%, 25%, and 15% for patients treated with RT alone.  Progression-free survival (PFS) and OS were also longer with PCV and RT than RT alone among patients with IDH-mutant non-codeleted tumors in both studies.

“Both studies demonstrated a 40% reduction in the risk of death (HR 0.59 RTOG, 0.60 EORTC) by adding neo/adjuvant PCV to RT in 1p19q codeleted anaplastic oligodendroglial tumors, with median survival of ~14 years (13.2 RTOG, 14.2 EORTC).  Even more remarkably, in this extremely long-term and mature analysis, 20-years after diagnosis, approximately 30% of patients with a co-deleted tumor remained progression-free and nearly 40% were still alive following PCV-chemoradiotherapy.  These trials, initiated nearly 30 years ago under the visionary leadership of Dr. Gregory Cairncross (RTOG), Martin van den Bent (EORTC) and colleagues, transformed our understanding of the clinical behavior of molecularly defined gliomas and contributed to the classification of gliomas used globally today.  Importantly, these extremely long-term results also show that early PCV can be associated with durable disease control and survival, especially among patients with 1p19q codeleted tumors,” stated Andrew B. Lassman, MD, chief of neuro-oncology at Columbia University Vagelos College of Physicians and Surgeons, Herbert Irving Comprehensive Cancer Center, and New York-Presbyterian Hospital, New York, NY, and the lead author of the NRG/RTOG 9402 EORTC manuscript.

This project was supported by NRG Oncology Operations grant U10CA180868, NRG Oncology SDMC grant U10CA180822, NCORP grant UG1CA189867, and the NRG Specimen Bank  grant U24CA196067 from the National Cancer Institute (NCI), part of the National Institutes of Health.  Dr. Lassman was also supported in part by the Rhodes Center for glioblastoma at New York Presbyterian Hospital, and NCI grants P30CA013696 and UG1CA189960.  

Citation

Lassman AB, Hoang-Xuan K, Polley MC, Brandes AA, Cairncross JG, Kros JM, Ashby LS, Taphoorn MJB, Souhami L, Dinjens WNM, Laack NN, Kouwenhoven MCM, Fink KL, French PJ, Macdonald DR, Lacombe D, Won M, Gorlia T, Mehta MP, van den Bent MJ. Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors. J Clin Oncol. 2022 Jun 22:JCO2102543. doi: 10.1200/JCO.21.02543. Epub ahead of print. PMID: 35731991.

About NRG Oncology

NRG Oncology conducts practice-changing, multi-institutional clinical and translational research to improve the lives of patients with cancer. Founded in 2012, NRG Oncology is a Pennsylvania-based nonprofit corporation that integrates the research of the legacy National Surgical Adjuvant Breast and Bowel Project (NSABP), Radiation Therapy Oncology Group (RTOG), and Gynecologic Oncology Group (GOG) programs. The research network seeks to carry out clinical trials with emphases on gender-specific malignancies, including gynecologic, breast, and prostate cancers, and on localized or locally advanced cancers of all types. NRG Oncology’s extensive research organization comprises multidisciplinary investigators, including medical oncologists, radiation oncologists, surgeons, physicists, pathologists, and statisticians, and encompasses more than 1,300 research sites located world-wide with predominance in the United States and Canada. NRG Oncology is supported primarily through grants from the National Cancer Institute (NCI) and is one of five research groups in the NCI’s National Clinical Trials Network.

www.nrgoncology.org